The FDA meeting in Q2 2026 is the next meaningful catalyst — monitor for meeting minutes and any announced trial design. Until then, no new data or financial updates are expected to drive the stock.
Price Chart
Executive Summary
Cognition Therapeutics announced a second philanthropic donation to extend its expanded access program (EAP) for zervimesine in dementia with Lewy bodies (DLB), and reiterated plans for an FDA meeting in Q2 2026 to discuss a registrational program. The press release contains no new clinical data, financial results, or regulatory decisions — it is a routine operational update with no material impact on the stock.
Key Facts
- A second philanthropic donation from Mr. Jeffrey Pechter will extend the EAP (COG1202) to provide two years of treatment for 32 enrolled DLB patients.
- Cognition expects to meet with the FDA Division of Psychiatry in Q2 2026 to discuss next steps for a registrational program for zervimesine in DLB psychosis.
- No new clinical data, financial results, or regulatory decisions were announced.
- The company is a clinical-stage biopharma with no approved products and no disclosed revenue.
Financial Impact
No financial figures disclosed; donation amount and company cash position not provided.
Risk Factors
- No approved products; zervimesine safety/efficacy not fully characterized.
- FDA meeting outcome uncertain; registrational program may be delayed or require additional studies.
- Clinical-stage biotech with no revenue and reliance on grants/donations for funding.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294793 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $0.7010 $0.7188 | ▲ +2.54% | ▲ +3.06% | $0.7196 (+2.65%) |
Jun 4, 2026 20w ago | 8-K | $1.36 $1.29 | ▼ −5.15% | ▼ −2.55% | $0.7196 (−47.09%) |
Jun 1, 2026 21w ago | Press Release | $1.25 $1.35 | ▲ +8.00% | ▲ +7.86% | $0.7196 (−42.43%) |
May 21, 2026 22w ago | Press Release | $1.25 $1.26 | ▲ +0.80% | ▲ +0.35% | $0.7196 (−42.43%) |
May 14, 2026 23w ago | Press Release | $1.20 $1.14 | ▼ −5.00% | ▼ −3.77% | $0.7196 (−40.03%) |
May 7, 2026 24w ago | 8-K | $1.21 $1.18 | ▼ −2.48% | ▼ −2.71% | $0.7196 (−40.53%) |
Apr 16, 2026 27w ago | Insider Cluster | $1.11 $1.19 | ▲ +7.21% | ▲ +5.99% | $0.7196 (−35.17%) |
Mar 26, 2026 30w ago | Press Release | $1.08 $0.7300 | ▼ −32.41% | ▼ −30.73% | $0.7196 (−33.37%) |
Mar 23, 2026 31w ago | Press Release | $1.13 $1.10 | ▼ −2.65% | ▼ −2.30% | $0.7196 (−36.32%) |
Mar 17, 2026 31w ago | Press Release | $1.15 $1.10 | ▼ −4.35% | ▼ −2.95% | $0.7196 (−37.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers